SOS
VRTX icon

Silver Oak Securities’s Vertex Pharmaceuticals VRTX Stock Holding History

Silver Oak Securities’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-381
Closed -$170K – 828
2025
Q2 		$170K Buy
+381
New +$176K 0.01% 655
2024
Q4 		– Sell
-1,219
Closed -$553K – 661
2024
Q3 		$553K Buy
1,219
+20
+2% +$9.61K 0.06% 318
2024
Q2 		$562K Buy
1,199
+283
+31% +$123K 0.08% 203
2024
Q1 		$383K Sell
916
-1,433
-61% -$606K 0.06% 260
2023
Q4 		$956K Buy
2,349
+1,355
+136% +$501K 0.13% 170
2023
Q3 		$346K Sell
994
-950
-49% -$332K 0.08% 206
2023
Q2 		$684K Buy
+1,944
New +$655K 0.11% 191
2022
Q4 		– Sell
-994
Closed -$346K – 489
2022
Q3 		$346K Buy
+994
New +$286K 0.08% 206

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Silver Oak Securities's VRTX Position: Q3 2025 in Review

Silver Oak Securities sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 381 shares — an estimated $170K sold.

Silver Oak Securities first reported a position in VRTX in Q3 2022 and held it in 8 quarters. The position peaked at $956K in Q4 2023. 1,521 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • Silver Oak Securities reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Silver Oak Securities sold 381 Vertex Pharmaceuticals shares in Q3 2025, an estimated $170K.
  • Silver Oak Securities first reported a position in Vertex Pharmaceuticals in Q3 2022 and held it in 8 quarters.
  • Silver Oak Securities's Vertex Pharmaceuticals position peaked at $956K in Q4 2023.
  • 1,521 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Silver Oak Securities's 13F filing for Q3 2025, filed 21 Oct 2025.